ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vaccination"

  • Abstract Number: 1607 • ACR Convergence 2021

    The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE

    Rebecca Sadun1, Mithu Maheswaranathan1, Megan Clowse2, Kai Sun1, Jennifer Rogers1, Jayanth Doss1, Lisa Criscione-Schreiber3 and Amanda Eudy1, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University School of Medicine, Durham, NC

    Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
  • Abstract Number: 0457 • ACR Convergence 2021

    Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination

    Michael Paley1, Parakkal Deepak2, Wooseob Kim2, Monica Yang3, Alex Carividi3, Emanuel Demissie3, Alia A. El-Qunni,2, Alem Haile2, Katherine Huang2, Baylee Kinnett2, Mariel Liebeskind2, Zhouming Liu2, Lily E. McMorrow2, Diana Paez3, Niti Pawar3, Dana Perantie2, Rebecca E. Schriefer2, Shannon Sides2, Mahima Thapa2, Sewuese Akuse4, Samantha Burdess2, Abbey Rose2, Lynne Mitchell2, Salim Chahin2, Matthew Ciorba2, Jonathan Graf5, Patricia Katz3, Mehrdad Matloubian3, Jane O'Halloran2, Rachel Presti2, Gregory Wu2, Sean Whelan2, William Buchser2, Lianne Gensler6, Mary Nakamura7, Ali H Ellebedy2 and Alfred Kim2, 1Washington University in St. Louis, Olivette, MO, 2Washington University School of Medicine, St. Louis, MO, 3University of California San Francisco, San Francisco, CA, 4Washington University School of Medicine, St Louis, MO, 5Ucsf, San Francisco, CA, 6Department of Rheumatology, University of California San Francisco, San Francisco, CA, 7UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
  • Abstract Number: 1616 • ACR Convergence 2021

    Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley

    Sukesh Sukumaran1, Reshma Patel2 and Deepika Singh3, 1Valley Children's Healthcare, Madera, CA, 2Valley Children's Hospital, Madera, CA, 3Valley Children Healthcare, Madera, CA

    Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
  • Abstract Number: 0640 • ACR Convergence 2021

    Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors

    Manjeet Bhamra1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2State University of New York, Syracuse, NY

    Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…
  • Abstract Number: 1843 • ACR Convergence 2021

    Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

    Jessica Gordon1, Kimberly Showalter1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier4, Richard Henry2, Nora Østbø2, Julia Nordlund2, Angelica Bourgeault2, Mara Canedo Ayala2, Marie-Nicole Discepola2, Andrea Carboni Jiménez2, Christopher Denton5, Luc Mouthon6, Brett Thombs7 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, 3Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, 4Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 6Hopital Cochin - Paris University, Paris, France, 7Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada

    Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
  • Abstract Number: 0649 • ACR Convergence 2021

    Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention

    Daniel Magliulo1, Stefanie Wade2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3BIDMC, Boston, MA

    Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
  • Abstract Number: 803 • 2019 ACR/ARP Annual Meeting

    Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment

    Kenan Barut 1, Amra Adrovic 2, Sezgin Sahin 3, Mehmet Yıldız 2, Oya Koker 2, Gamze Yalcin 2, Omer Faruk Beser 4, Bekir Kocazeybek 5, Pelin Yuksel 5 and Ozgur Kasapcopur6, 1Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, 2Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, 3Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 4Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, 5Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, 6Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is…
  • Abstract Number: 1804 • 2019 ACR/ARP Annual Meeting

    Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients

    Emma Stevens1, Michael Weinblatt 1, Elena Massarotti 2, Frances Griffin 1, Srinivas Emani 1 and Sonali Desai 3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical S, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) and other systemic diseases (SD) are at an increased risk of developing Herpes Zoster (HZ) due to either the…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology